Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Daneshmand on the Investigation of Erdafitinib in NMIBC With FGFR2/3 Alterations

April 3rd 2023

Siamak Daneshmand, MD, discusses the rationale for investigating erdafitinib in patients with recurrent, intermediate-risk non–muscle invasive bladder cancer harboring FGFR3 or FGFR2 alterations.

Treatment Approaches for Patients with RCC and Bone Metastases

March 31st 2023

Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.

Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

March 31st 2023

The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.

Advanced RCC Treatment Options Post-Progression

March 31st 2023

Experts on renal cell carcinoma discuss post-progression treatment options for RCC.

Considerations in Advanced RCC Treatment Selection

March 31st 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.

Front Line Trials in Advanced RCC

March 24th 2023

Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.

Patient Profile: A 67-Year-Old Man With Metastatic Clear Cell RCC

March 24th 2023

Benjamin Garmezy, MD, presents the case of a 67-year-old man diagnosed with advanced renal cell carcinoma.

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

March 23rd 2023

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

March 23rd 2023

Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

Christopher W. Ryan, MD, discusses the role of adjuvant pembrolizumab in renal cell carcinoma, the use of immunotherapy-based combinations in the frontline setting for metastatic renal cell carcinoma, and key data presented at the 2023 Genitourinary Cancers Symposium in bladder cancer and prostate cancer.

Renal Cell Carcinoma Histology and Risk Stratification

March 17th 2023

Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.

Overview of Renal Cell Carcinoma

March 17th 2023

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, open the discussion with an overview of renal cell carcinoma.

CaboPoint Data Underscore Potential for Cabozantinib Following Frontline Combination Therapy in Advanced RCC

March 16th 2023

Laurence Albigès, MD, PhD, discusses what inspired the launch of the CaboPoint study examining second-line cabozantinib in patients with advanced renal cell carcinoma, the efficacy of this approach, and the next steps for this research.

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

When the fully human IgG4 monoclonal antibody SRK-181 was given as a monotherapy or in combination with anti–PD-1 or PD-L1 agents in patients with locally advanced or metastatic solid tumors, it was found to be generally well tolerated and to demonstrate early indications of efficacy.

Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

March 15th 2023

Mehmet Asim Bilen, MD, presents a profile of a 65-year-old woman with metastatic renal cell carcinoma for discussion.

Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

March 15th 2023

Moshe Ornstein, MD, MA, starts a conversation on how patients with metastatic renal cell carcinoma are classified by risk, and how risk category influences approaches to systemic therapy.

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

March 10th 2023

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

The combination of cabozantinib and atezolizumab elicited responses in patients with non–clear cell renal cell carcinoma, according to extended follow-up data from the phase 1b COSMIC-021 trial.

PFS Benefit With Frontline Nivolumab/Cabozantinib Vs Sunitinib Is Independent of PD-L1 or c-MET Status in Advanced RCC

March 9th 2023

The progression-free survival benefit associated with the combination of nivolumab plus cabozantinib compared with sunitinib was largely independent of PD-L1 and c-MET status in previously untreated patients with advanced or metastatic renal cell carcinoma.